Objectives: A high loading dose of statins has been showed to reduce post procedural events in patients undergoing percutaneous coronary intervention (PCI). In this study, we investigated the possible protective effects of rosuvastatin in Egyptian patients with stable or unstable angina undergoing PCI.Patients & Methods: Our study was carried on 75 patients suffering from coronary artery disease ( stable or unstable angina) who were planned for elective PCI and had no contraindication to statin therapy. The cases were divided into 3 groups, (Group I) included 35 patients who were not on statin therapy and received rosuvastatin 20 mg within 24 hours prior to PCI, (Group II) included 20 patients who were already on chronic statin therapy prior to PCI and continued on it & (Group III) included 20 patients who were not on statins and didn’t receive any lipid lowering agent prior to PCI. Creatine kinase-MB, troponin-I, were measured at baseline , 8 and 24 hours after the procedure & additional samples were obtained if the patients showed signs or symptoms of myocardial ischemia. The study end point was the incidence of periprocedural myocardial injury in patients undergoing elective PCI.Results: In our study, we found that loading dose of rosuvastatin 20 mg was associated with a reduction of periprocedural myonecrosis more than chronic statin therapy and both of them were associated with a reduction of periprocedural myonecrosis more than non-statins users in patients with stable or unstable angina. The postprocedural elevation in CK-MB and troponin-I at 8 hours and 24 hours was significantly lower in the rosuvastatin group compared with the chronic statin’s group. Both statins groups showed significantly lower level of CK-MB and troponin-I, at 8 hours and 24 hours compared with non-statins users group. Conclusions: A single, high loading dose (20 mg) of rosuvastatin within 24 hours prior to PCI reduces periprocedural myocardial injury in patients with stable or unstable angina